18889881171
Kalkine 0
countryflagUS

bioMérieux S.A

Healthcare US BMXMF

129.732USD
-(-%)

Last update at 2025-05-16T13:30:00Z

Day Range

129.73129.73
LowHigh

52 Week Range

90.23111.08
LowHigh

Fundamentals

  • Previous Close 129.73
  • Market Cap13120.62M
  • Volume0
  • P/E Ratio31.03
  • Dividend Yield0.82%
  • EBITDA771.60M
  • Revenue TTM3701.20M
  • Revenue Per Share TTM31.41
  • Gross Profit TTM 2008.70M
  • Diluted EPS TTM3.58

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 580.50M 774.30M 525.40M 347.30M 320.90M
Minority interest 11.80M 2.90M 50.20M 50.70M 74.00M
Net income 452.40M 601.10M 404.40M 272.80M 256.60M
Selling general administrative 253.20M 242.60M 200.00M 182.20M 165.20M
Selling and marketing expenses 701.50M 575.70M 589.30M 567.60M 480.30M
Gross profit 2008.60M 1963.70M 1753.60M 1466.60M 1302.30M
Reconciled depreciation 277.00M 231.00M 210.80M 189.50M 157.90M
Ebit 665.60M 802.90M 598.10M 389.70M 364.40M
Ebitda 942.60M 1033.90M 808.90M 579.20M 522.30M
Depreciation and amortization 277.00M 231.00M 210.80M 189.50M 157.90M
Non operating income net other - - - - 0.00000M
Operating income 587.20M 784.30M 595.10M 370.70M 343.60M
Other operating expenses 2925.30M 2575.20M 2522.20M 2286.40M 2060.30M
Interest expense 4.10M 9.10M 24.90M 22.10M 16.90M
Tax provision 140.10M 175.60M 121.50M 77.80M 65.20M
Interest income 1.20M 1.70M 1.50M - -
Net interest income -5.20000M -9.80000M -28.50000M -20.30000M -14.70000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 140.10M 175.60M 121.50M 77.80M 65.20M
Total revenue 3589.00M 3376.20M 3118.10M 2674.80M 2421.40M
Total operating expenses 1344.90M 1162.70M 1157.70M 1078.20M 941.20M
Cost of revenue 1580.40M 1412.50M 1364.50M 1208.20M 1119.10M
Total other income expense net -6.70000M -10.00000M -69.70000M -23.40000M -22.70000M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 440.40M 598.00M 402.60M 269.50M 255.90M
Net income applicable to common shares 452.40M 601.10M 404.40M 272.80M 256.50M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 5186.60M 4616.80M 3927.80M 3781.90M 3389.60M
Intangible assets 625.00M 411.50M 430.80M 508.40M 507.40M
Earning assets - - - - -
Other current assets 38.80M 43.70M 27.60M 14.00M 15.50M
Total liab 1543.70M 1442.20M 1446.50M 1527.30M 1386.30M
Total stockholder equity 3604.20M 3123.20M 2431.10M 2203.90M 1929.30M
Deferred long term liab - - - - 0.00000M
Other current liab 122.50M 95.90M 85.60M 73.60M 59.80M
Common stock 12.00M 12.00M 12.00M 12.00M 12.00M
Capital stock 12.00M 12.00M 12.00M 12.00M 12.00M
Retained earnings 452.40M 601.10M 404.40M 272.80M 256.60M
Other liab 94.20M 123.70M 170.20M 203.50M 181.20M
Good will 812.50M 669.50M 629.40M 652.50M 616.50M
Other assets 0.10M 0.10M -0.10000M -0.10000M 0.20M
Cash 552.60M 803.50M 389.20M 275.00M 280.10M
Cash and equivalents - - - - -
Total current liabilities 1131.10M 955.90M 923.90M 1170.20M 756.70M
Current deferred revenue 552.20M 520.80M 502.30M 446.10M 419.80M
Net debt -47.20000M -341.00000M 92.10M 317.30M 266.90M
Short term debt 187.00M 99.70M 128.90M 438.60M 100.20M
Short long term debt 160.80M 99.70M - 438.60M 96.40M
Short long term debt total 505.40M 462.50M 481.30M 592.30M 547.00M
Other stockholder equity 3139.80M 2510.10M 2014.70M 1919.10M 1660.70M
Property plant equipment 1369.90M 1224.80M 1068.60M 1025.20M 899.10M
Total current assets 2216.60M 2207.10M 1661.60M 1438.50M 1295.50M
Long term investments - - - 42.10M 59.10M
Net tangible assets 2166.70M 2042.10M 1371.10M 1043.00M 799.00M
Short term investments -19.80000M -27.50000M -10.70000M -10.40000M -13.00000M
Net receivables 740.10M 701.40M 682.10M 639.90M 578.40M
Long term debt 224.80M 362.80M - 153.70M 412.90M
Inventory 737.20M 634.60M 541.90M 494.70M 414.90M
Accounts payable 269.40M 239.50M 207.10M 211.90M 176.90M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 12.80M 12.50M 14.20M 16.10M 16.20M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 2969.90M 2409.60M 2266.30M 2343.50M 2093.90M
Capital lease obligations 119.90M 122.40M - - 37.70M
Long term debt total - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -528.10000M -0.40000M -2.30000M -2.40000M -5.40000M
Change to liabilities 9.90M 24.20M 4.70M 32.90M 13.10M
Total cashflows from investing activities -528.10000M -307.30000M -265.20000M -282.20000M -413.10000M
Net borrowings 14.30M -50.10000M -134.50000M -69.20000M 105.50M
Total cash from financing activities -244.20000M -127.00000M -176.20000M -133.90000M 52.70M
Change to operating activities 71.90M -21.80000M 77.90M 28.50M 36.30M
Net income 440.50M 598.20M 402.70M 269.70M 255.50M
Change in cash -258.60000M 416.00M 107.30M -14.20000M 9.60M
Begin period cash flow 787.30M 371.30M 264.00M 278.20M 260.40M
End period cash flow 528.70M 787.30M 371.30M 264.00M 270.00M
Total cash from operating activities 475.10M 811.10M 582.80M 407.90M 386.90M
Issuance of capital stock 0.00000M 0.00000M - - -
Depreciation 277.00M 231.00M 210.80M 189.50M 157.90M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid -101.20000M -73.10000M -22.50000M -41.30000M 40.20M
Change to inventory -92.10000M -62.40000M -82.90000M -71.00000M -27.30000M
Change to account receivables -145.60000M 23.60M -80.40000M -57.30000M -30.60000M
Sale purchase of stock -157.20000M -3.80000M -18.40000M 0.00000M 0.00000M
Other cashflows from financing activities -0.10000M 18.20M -0.80000M -92.60000M 92.90M
Change to netincome -98.40000M -1.40000M 30.70M -5.60000M -45.10000M
Capital expenditures 286.70M 290.10M 277.50M 272.50M 226.80M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -155.90000M -36.40000M -80.70000M -66.90000M -1.60000M
Stock based compensation 13.00M 12.40M 9.90M 9.40M 6.70M
Other non cash items -3.60000M 24.00M 42.30M 38.80M 35.90M
Free cash flow 188.40M 521.00M 305.30M 135.40M 160.10M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMXMF
bioMérieux S.A		 - -% 129.73 31.03 22.73 3.52 3.19 3.54 15.48
TMO
Thermo Fisher Scientific Inc		 -0.22 0.05% 411.84 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.475 0.24% 195.63 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -0.69 0.61% 113.08 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 1.85 0.36% 519.95 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

bioMérieux S.A

376 Chemin De l?Orme, Marcy l'Étoile, France, 69280

Key Executives

Name Title Year Born
Mr. Alexandre Merieux Chairman & CEO 1974
Mr. Pierre Boulud Chief Operating Officer of Clinical Operations 1971
Mr. Frederic Beseme Head of CSR 1956
Mr. Guillaume Bouhours Exec. VP of Purchasing and Information Systems & CFO 1976
Sylvain Morgeau Investor Relations NA
Ms. Valerie Leylde Exec. VP of HR, Communications & CSR NA
Mr. François Lacoste Exec. VP of R&D NA
Mr. Mark Miller Exec. VP of Medical Affairs NA
Mr. Pierre Charbonnier Exec. VP of Quality, Manufacturing & Supply Chain NA
Mr. Yasha Mitrotti Exec. VP of Industrial Microbiology NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.